Neonatal pulmonary adaptation
Conditions
Interventions
Trade Name: Ventoline Evohaler
Product Name: Ventoline Evohaler
Product Code: R03AC02
Pharmaceutical Form: Inhalation vapour, solution
I
Sponsors
Children's Hospital, Helsinki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The study population consists of 62 healthy singleton newborn infants delivered by elective cesarean section at 37 + 0 to 41+6 gestational weeks. Are the trial subjects under 18? yes Number of subjects for this age range: 62 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1) clinically significant congenital malformations, 2) birth weight 200 bp for more than 5 min, 5) relevant medication of the mother, e.g. albetol, beta-agonists (e.g. salbutamol, salmeterol), corticosteroids and 6) the suspicion of/confirmed pneumothorax or infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The aim of this study is to evaluate whether the respiratory status, measured by a transthoracal ultrasound method and lung compliance, of newborns infants born by CS can be improved by inhaled salbutamol at 30-60 minutes of age.;Secondary Objective: To study whether infants at risk of developing transient tachypnea of the newborn can be identified early using a transthoracal ultrasound method.;Primary end point(s): Lung compliance and Ultrasound measurements at 3-6 hours of age.;Timepoint(s) of evaluation of this end point: 3-6 hours of age | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): No secondary endpoints;Timepoint(s) of evaluation of this end point: No time for this end point | — |
Countries
Finland
Contacts
Public ContactChildren's Hospital
Children's Hospital
Outcome results
None listed